Green Cross Cell corporation (KOSDAQ:A031390) agreed to acquire additional 68.8% stake in Lymphotec, Inc. from Toyo Seikan Group Holdings, Ltd. (TSE:5901) on March 22, 2018. Green Cross Cell corporation will acquire 59,251 shares in Lymphotec, Inc. After the deal, Green Cross will hold 83.3% stake in Lymphotec from 14.5% stake earlier. Deal is expected to complete by April 2, 2018.
Green Cross Cell Corporation
Equities
A031390
KR7031390008
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |